Clinical Trials Logo

Hyperkinesis clinical trials

View clinical trials related to Hyperkinesis.

Filter by:

NCT ID: NCT00246207 Completed - Clinical trials for Attention Deficit Disorder With Hyperactivity

CONCERTA (OROS Methylphenidate Hydrochloride) for the Treatment of Attention Deficit Hyperactivity Disorder in Adults

Start date: March 2005
Phase: Phase 3
Study type: Interventional

The purpose of this pilot study is to evaluate the safety, tolerability and potential effectiveness of CONCERTA® (methylphenidate hydrochloride extended-release tablets), a central nervous system (CNS) stimulant for the treatment of adults with Attention Deficit Hyperactivity Disorder (ADHD).

NCT ID: NCT00228046 Completed - Clinical trials for Attention Deficit Disorder With Hyperactivity

Medication Strategies for Treating Aggressive Behavior in Youth With Attention Deficit Hyperactivity Disorder

Start date: January 2004
Phase: Phase 4
Study type: Interventional

This study will assess whether adding a mood stabilizer, divalproex sodium, to stimulant treatment is more effective than stimulant treatment alone in reducing aggressive behavior among children with attention deficit hyperactivity disorder (ADHD).

NCT ID: NCT00221962 Completed - Clinical trials for Attention Deficit Hyperactivity Disorder

Study of Aripiprazole (Abilify) in Children With ADHD (Attention Deficit Hyperactivity Disorder)

Start date: April 2005
Phase: Phase 4
Study type: Interventional

To look at the cognitive effects of abilify in children with a primary diagnosis of Attention Deficit Hyperactivity Disorder. To examine the safety, effectiveness and tolerability of abilify in children with a primary diagnosis of Attention Deficit Hyperactivity Disorder.

NCT ID: NCT00218543 Completed - Clinical trials for Attention Deficit Disorder With Hyperactivity

Atomoxetine for Treating Cocaine Abuse in Adults With Attention Deficit Hyperactivity Disorder (ADHD)

Atom
Start date: June 2004
Phase: Phase 2
Study type: Interventional

Studies have shown that individuals with attention deficit hyperactivity disorder (ADHD) are at greater risk for having a substance use disorder compared to people who do not have ADHD. Rates of cocaine abuse in adults with ADHD are significantly higher than they are in adults who do not have ADHD. Some clinicians suggest that adults with ADHD may abuse cocaine in order to self-medicate their ADHD symptoms. Atomoxetine is a drug that has been effective in treating ADHD. This study will evaluate the effectiveness of atomoxetine in reducing cocaine use in people with ADHD who abuse cocaine.

NCT ID: NCT00218322 Completed - Clinical trials for Substance-Related Disorders

Effectiveness of ATMX in Treating Adolescents With ADHD and SUD

Start date: September 2004
Phase: Phase 4
Study type: Interventional

Adolescents with attention deficit hyperactivity disorder (ADHD) often develop substance use disorders (SUD). The purpose of this study is to evaluate the effectiveness of atomoxetine in treating adolescents dually diagnosed with ADHD and SUD.

NCT ID: NCT00216918 Completed - Clinical trials for Attention Deficit Hyperactivity Disorder

Neuropsychological Functioning in Children With Attention-Deficit/Hyperactivity Disorder.

Start date: September 2005
Phase: Phase 4
Study type: Interventional

The purpose of this study is to evaluate the change in neuropsychological status from baseline to 6 months post-initiation of atomoxetine treatment in children ages 6 to 10.5 diagnosed with ADHD.

NCT ID: NCT00214981 Completed - ADHD Clinical Trials

Evaluate the Safety and Efficacy of Modafinil in Children and Adolescents With ADHD

Start date: September 2003
Phase: Phase 3
Study type: Interventional

Primary objective of this study is to evaluate the safety of treatment with modafinil film-coated tablet.

NCT ID: NCT00202605 Completed - Clinical trials for Attention Deficit Disorder With Hyperactivity

Safety and Efficacy of SPD465 in Adults With ADHD

Start date: September 29, 2005
Phase: Phase 2
Study type: Interventional

The purpose of the study is to evaluate how safe and how well SPD465 works compared to placebo in adults with ADHD. It is hypothesized that SPD465 will achieve an extended duration of clinical benefit.

NCT ID: NCT00192023 Completed - Clinical trials for Attention Deficit Hyperactivity Disorder

An Italian Study of the Efficacy of Atomoxetine in the Treatment of Children and Adolescents With Attention-Deficit/Hyperactivity Disorder (ADHD) and Comorbid Oppositional Defiant Disorder (ODD).

Start date: October 2004
Phase: Phase 3
Study type: Interventional

The study is a phase IIIb multicentre, randomised, placebo controlled, trial in paediatric patients with Attention-Deficit/Hyperactivity (ADHD) and Oppositional Defiant Disorder (ODD). The primary aim of the study is to evaluate the efficacy of atomoxetine in improving ADHD and ODD symptoms in patients non responders to a previous psychological intervention with parent support. Moreover, the potential role of atomoxetine in treating other psychiatric comorbid conditions associated with ADHD and ODD will be assessed.

NCT ID: NCT00191945 Completed - Clinical trials for Attention Deficit Hyperactivity Disorder

Efficacy and Safety of Atomoxetine in Children With Recent Diagnosis of Attention-Deficit/Hyperactivity Disorder (ADHD)

Start date: May 2005
Phase: Phase 3
Study type: Interventional

Double blinded clinical trial placebo controlled in 153 children (planned enrollment) with recent diagnosis of ADHD. Patients will be randomized to atomoxetine or placebo arm (2:1). The double blinded period will last 12 weeks and the treatment open phase will last up to 1 year, and atomoxetine treatment will be administered. A gatekeeper strategy will be employed for sequentially testing the secondary objectives.